Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Figures & data

Table 1. Oral hypoglycemic agents used in type 2 DM.

Oral hypoglycemic drugs (Brand name)	Chemical name and formula	Chemical structure	Mechanism of primary action	Typical dosage/blood levels	Cmax & AUC of drug
Metformin (Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet)	3-(diaminomethylidene)-1,1-dimethylguanidine C4H11N5		Increases glucose transport across the cell membrane in skeletal muscle. Acts only in the presence of endogenous insulin	500–850 mg daily. Maximum daily dose 2550 mg.	Cmax = 1713.54 ± 508.75 ng/ml AUC = 9284.88 ± 2155.57 ng.h/ml [14]
Glipizide (Glucotrol)	N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide C21H27N5O4S		Binds to ATP-sensitive potassium-channel receptors on pancreatic cell surface, decreasing potassium conductance, and causing depolarization of membrane. This stimulates calcium ion influx through voltage-sensitive calcium channels, inducing secretion, or exocytosis, of insulin.	5 mg administered 30 min before meals. Maximum dose 40 mg daily.	Cmax = 523 ± 60 ng/ml AUC = 1897ng.h/ml [15]
Glyburide/ Glibenclamide (Micronase, Diabeta, Glynase Prestab)	5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxy benzamide C23H28ClN3O5S		Same as glipizide.	2.5–5 mg daily of regular tablets or 1.5–3 mg daily of micronized tablets. Maximum dose 1.25–20 mg of regular tablets and 0.75–12 mg of micronized tablets.	Cmax = 147.1 ± 23.6 ng/ml AUC = 525.7 ± 28.1 ng.h/ml [16]
Tolbutamide (Orinase)	1-butyl-3-(4-methylphenyl)sulfonylurea C12H18N2O3S		Same as glipizide.	500 mg.	Cmax = 63 ± 11 μg/ml AUC = 721 ± 94 μg.h/ml [17]
Nateglinide (Starlix)	(2S)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid C19H27NO3		Stimulates pancreas to produce insulin (similar to the sulfonylureas). Appears to have a faster onset and a shorter duration of action than sulfonylureas. May prevent the rapid, transient rise in blood glucose that occurs immediately following a meal.	60 or 120 mg three times daily.	Cmax = 3.09 ± 1.64 μg/ml AUC = 6.93 ± 1.99 μg.h/ml [18]
Repaglinide (Prandin)	2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2 -oxoethyl]benzoic acid C27H36N2O4		Stimulates insulin production. Rapid onset and short duration of action.	Immediately before a meal.	Cmax = 30.96 ± 9.06 μg/l AUC = 36.03 ± 6.00 μg.h/l [19]
Rosiglitazone maleate (Avandia)	5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione C18H19N3O3S		Attaches to insulin receptors on cells throughout the body increasing insulin sensitivity.	4–8 mg daily.	Cmax = 724.3 ± 135.7 ng/ml AUC = 4024 ± 956 ng.h/ml [20]
Pioglitazones (Actos)	5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2 ,4-dioneC18H19N3O3S C19H20N2O3S		Same as rosiglitazone.	15–45 mg daily.	Cmax= 932 ± 335 ng/ml AUC = 8.61 ± 3.66 mg.h/l [21]
Miglitol (Glycet)	1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol C8H17NO5		Inhibitors of intestinal α-glucosidase enzymes, resulting in delayed breakdown of carbohydrates and delayed glucose absorption, reducing postprandial hyperglycemia.	25–100 mg three times before meals.	Cmax = 1883,9 ± 912.4 μg/l AUC = 7592.7 ± 4207.4 μg.h/l [22]
Acarbose (Precose) Alpha-glucosidase inhibitors	(3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]o xy-6-(hydroxymethyl)oxane-2,3,4-triol C25H43NO18		Slows down the actions of α-amylase and α -glucosidase enzymes.	25–100 mg three times daily.	Data not available.
Sitagliptin	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one C16H15F6N5O		Inhibits dipeptidylpeptidase-4, increases insulin secretion and lowers glucagon secretion.	100 mg once daily.	Cmax = 706nMAUC = 7.13μM.h [23]

Table 2. Lipid-lowering and anti-hypertensive drugs commonly used in type 2 DM management.

	Chemical name and formula	Chemical structure	Mechanism of primary action	Typical dosage/blood levels	Cmax & AUC of drug
Lipid- lowering drugs (Brand name)
Lovastatin (Mevacor, Lipivas, etc.)	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate C24H36O5		Readily hydrolyzes in vivo to the corresponding β-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Stimulates the production of low-density lipoprotein receptors in the liver.	10–80 mg daily.	Cmax = 5.57 ± 0.61 ng/ml AUC = 39.45 ± 3.23 ng.h/ml [25]
Pravastatin (Mevastatin, Selectin, Elisor, etc.)	(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid C23H36O7		Inhibits HMG-CoA reductase and hepatic synthesis of VLDL-C, reducing circulating cholesterol and LDL-C.	40 mg daily. Maximum dose is 80 mg.	Cmax = 115.8 ± 77.5 ng/ml AUC = 259.0 ± 133.4 ng.h/ml [26]
Simvastatin (Lipex, Cholestat, Zocor, etc.)	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate C25H38O5		The six-membered lactone ring of simvastatin is hydrolyzed in vivo to generate mevinolinic acid, an active metabolite structurally similar to HMG-CoA. Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase.	5–80 mg daily.	Cmax = 16.3 ± 81.4 ng/ml AUC = 93.5 ± 70.1 ng.h/ml [27]
Atorvastatin (Lipitor, Tulip, Torvast, etc.)	(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid C33H35FN2O5		Selectively and competitively inhibits HMG-CoA reductase.	20–40 mg daily.	Cmax = 44.7 ± 61.3 ng/ml AUC = 164.7 ± 58.1 ng.h/ml [27]
Fluvastatin (Lescol, Cranoc, Canef, etc.)	(E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid C24H26FNO4		Selectively and competitively inhibits HMG-CoA reductase.	20–80 mg daily.	Cmax = 60.81 ± 38.26 ng/ml AUC = 246.97 ± 141.95 ng.h/ml [28]
Rosuvastatin (Crestor)	3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid C22H28FN3O6S		Competitive inhibitor of HMG-CoA reductase.	10–40 mg daily.	Cmax = 12.3 ± 7.0 ng/ml AUC = 124 ± 71 ng.h/ml [29]
Gemfibrozil (Lipozid, Lopid, Bolutol, Gemlipid, etc.)	5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid C15H22O3		Increases the activity of extrahepatic LPL, increasing lipoprotein triglyceride lipolysis. Inhibits synthesis and increases the clearance of apolipoprotein B.	600 mg twice a day. Maximum daily dose 1200 mg.	Cmax = 18.57 ± 6.61 μg/ml AUC = 75.19 ± 26.30 μg.h/ml [28]
Colestipol (Cholestabyl, Colestid)	N'-(2-aminoethyl)-N-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine; 2-(chloromethyl)oxirane C11H28ClN5O		A non-absorbed, lipid-lowering polymer. Binds bile acids in the intestine, impeding their reabsorption. This upregulates cholesterol 7-(alpha)-hydroxylase, increasing the conversion of cholesterol to bile acids.	2–16 grams (tablets) or 5–30 grams for the granules per day.	Data not available.
Fenofibrate (Antara, Lipidil, Procetofen, etc.)	propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate C20H21ClO4		Activates Peroxisome proliferator-activated receptor alpha, increasing lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apolipoprotein C-III.	40–120 mg per day.	Cmax = 9.00 μg/ml AUC = 56.4 μg.h/ml [30]
Niacin (Diacin, Daskil, Nicoside, Simcor, etc.)	pyridine-3-carboxylic acid C6H5NO2		Binds to nicotinate D-ribonucleotide pyrophsopate phosphoribosyltransferase, nicotinic acid phosphoribosyltransferase, nicotinate N-methyltransferase and the niacin receptor. Decreases esterification of hepatic Tg.	Recommended daily allowance range from 2 to 18 mg a daily.	Cmax = 4.61 ± 1.30 μg/ml AUC = 11.6 ± 1.24μg.h/ml [31]
Anti-hypertensive drugs (Brand name)
Ramipril (Acovil, Vesdil, Delix, etc.)	(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid C23H32N2O5		Competes with angiotensin I for binding at the angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II.	2.5–20 mg daily.	Cmax = 16.6 ± 13.4 ng/ml AUC = 39.5 ± 31.2 ng.h/ml [32]
Lisinopril (Zestril, Linopril, Lisipril, etc.)	(2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid C21H31N3O5		Competes with angiotensin I for its binding site on ACE.	10–40 mg daily.	Cmax = 79.8 ± 39.4 μg/ml AUC = 992.8 ± 520.5 μg.h/ml [33]
Amlodipine (Norvasc, Amvaz, Lotrel, Lipinox, etc.)	O3-ethyl O5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate C20H25ClN2O5		Inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes, causing dilation of coronary and systemic arteries.	5–10 mg once daily.	Cmax = 19.8 ± 6.7 ng/ml AUC = 359.2 ± 129.5 ng.h/ml [34]
Chlorthalidone (Thalitone, Oradil, Zambesil, Hygroton, etc.)	2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide C14H11ClN2O4S		Indirectly increases potassium excretion via the sodium-potassium exchange mechanism by increasing the delivery of sodium to the distal renal tubule.	25–100 mg once daily.	Cmax = 3.15 ± 0.52 μg/ml AUC = 5.55 ± 1.58 μg.h/ml [35]
Losartan (Cozaar, Lacidipine, Hyzaar, etc.)	[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol C22H23ClN6O		Interferes with binding of angiotensin II to angiotensin II AT1-receptor in vascular smooth muscle and adrenal gland.	50–100 mg daily.	Cmax = 351.0 ± 167.57 ng/ml AUC = 497.76 ± 171.90 ng.h/ml [36]
Captopril (Lopril, Acepril, Apopirl, Capoten, etc.)	(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid C9H15NO3S		Competes with angiotensin I for binding at the ACE, blocking the conversion of angiotensin I to angiotensin II.	25–150 mg daily. Maximum dose is 450 mg.	Cmax = 234 ng/ml AUC = 15.1μg.h/ml [37]
Furosemide (Diurin, Lasix, Nadis, Salurex, Uritol, etc.)	4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid C12H11ClN2O5S		Inhibits the reabsorption of sodium and chloride in ascending limb of the loop of Henle, increases the urinary excretion of sodium, chloride, water, potassium, hydrogen, calcium, magnesium, ammonium, and phosphate.	40 mg twice daily.	Cmax = 1087 ± 262 ng/ml AUC = N/A [38]
Metoprolol (Lopressor, Toprol, Prelis, Betaloc, etc.)	1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol C15H25NO3		Competes with adrenergic neurotransmitters (catecholamines) for binding at beta(1)-adrenergic receptors in heart and vascular smooth muscle resulting in decrease in heart rate, cardiac output, and blood pressure.	100–450 mg daily.	Cmax = 114.62 ± 32.92 μg/l AUC = 2096.45 ± 791.79 μg.h/l [39]
Nifedipine (Adalat, Afeditab, Procardia, Glopir, Oxcord, etc.)	dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate C17H18N2O6		Inhibits influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel causing dilation of the coronary and systemic arteries.	10–20 mg daily.	Cmax = 36.55 ± 6.76 ng/ml AUC = 347.06 ± 51.61 ng.h/ml [40]
Atenolol (Atcardil, Corotenol, Tenormin, Xaten, etc.)	2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide C14H22N2O3		Competes for binding at beta(1)-adrenergic receptors in heart and vascular smooth muscle, inhibiting sympathetic stimulation, resulting in lowered systolic and diastolic blood pressure.	50–100 mg once daily.	Cmax = 709 ± 221 ng/ml AUC = 6120 ± 2171 ng.h/ml [41]

Table 3. FRAP value of some drugs used in the management of Type 2 DM.

		FRAP per tablet/capsule (μmol)
	Mol. Mass	Water	HCl	NaOH	Ethanol
Hypoglycemic agent
Metformin HCl (Brand A), 500 mg	165.6	–	–	–	–
Metformin HCl (Brand B), 500 mg	165.6	–	–	–	–
Chlopropamide, 250mg	276.7	–	–	–	–
Gliclazide, 80 mg	323.4	–	–	740	543
Glipizide, 5 mg	445.5	–	–	–	–
Tolbutamide, 500 mg	270.4	–	–	–	–
Pioglitazone, 2 mg	356.4	–	–	202	182
Rosiglitazone, 2 mg	357.4	–	–	19	9
Glibenclamide, 5 mg	494	–	–	–	–
Lipid- lowering agent
Fluvastatin sodium, 40 mg	433.5	–	–	–	–
Simvastatin, 10 mg	418.6	23	26	–	14
Pravastatin sodium, 10 mg	424.5	–	–	–	–
Lovastatin, 20 mg	404.5	–	–	–	–
Acipimox, 250 mg	154.1	–	–	–	–
Bezafibrate, 400 mg	361.8	–	–	–	–
Gemfibrozil, 900 mg	250.3	–	–	–	–
Fenofibrate, 300 mg	260.8	–	–	–	–
Probucol, 250 mg	519.6	–	–	–	223
Rosuvastatin, 10 mg	481.5	–	–	–	–
Nicotinic acid, 500 mg	123.1	–	–	–	100
Atorvastatin calcium, 10 mg	1209.4	–	–	–	–
Antihypertensive agent
Metoprolol, 50 mg	267.4	–	–	22	42
Doxazosin mesylate, 5 mg	451.5	–	–	–	16
Tritace, 5 mg	416.5	–	–	13	–
Valsartan, 80 mg	435.5	–	–	427	1962
Amlodipine, 5 mg	408.9	–	–	27	22

FRAP: ferric reducing antioxidant power; HCl: hydrochloric acid; NaOH: sodium hydroxide; –: no detectable FRAP.

Table 4. Antioxidant effects of drugs commonly used in treatment of diabetes: (a) Oral hypoglycemic drugs; (b) Lipid-lowering and anti-hypertensive drugs.

Subject characteristics	Study description/duration of treatment	Outcome/biomarkers investigated	Results/comments
Type 2 DM patients [46]	Glipizide alone (15 mg/day) [n = 74] Glipizide (15 mg/day) with Aralia root bark extract (2.7 g/day) [n = 74] 8 weeks	HbA1c, fasting plasma glucose, 2h-postprandial plasma glucose, TC, and LDL-C	Both treatments decreased HbA1c (from 7.3 to 6.4% in combination group and from 6.9% to 6.5% in glipizide alone), compared to baseline (p < 0.05).
Type 2 DM patients [47]	Glibenclamide (5 mg/day) [n = 15] Gliclazide (80 mg/day) [n = 15] 12 weeks	Plasma lipid peroxides and plasma TRAP	Gliclazide significantly lowered plasma lipid peroxides (from 18.2 ± 3.9 to 13.3 ± 3.8 μmol/l), increased plasma TRAP (from 997.8 ± 132.5 to 1155.6 ± 143 μmol/l), compared to baseline control (p = 0.0001).
Type 2 DM patients Healthy, age, and gender-matched controls [48]	(1) Gliclazide 80–240 mg/day [n = 33] (2) Glibenclamide 10–15 mg/day [n = 30] (3) Metformin 1500 mg/day [n = 29] (4) Healthy, age, and gender-matched controls [n = 28] All Type 2 DM subjects already on antidiabetic agents (gliclazide, glibenclamide, or metformin) for ≥ 6 months before enrollment into study	TAS and plasma levels of o-Lab	In group 1, both the o-LAb level (236.6mIU/ml) and TAS (1.39 mmol/l) were similar to those of control group. o-Lab level (435.7mIU/ml, p < 0.05) was highest and TAS (0.85 mmol/l, p < 0.05) was lowest in group 3, compared with control.
Newly diagnosed Type 2 DM subjects [49]	Metformin or gliclazide uptitrated until good glycemic control was achieved, (up to 2550 mg/day for metformin and of 240 mg/day for gliclazide) [n = 26] 12 weeks	Urinary 8-iso-PGF2α, plasma vitamins A and E	Metformin significantly decreased 8-iso-PGF2α (from 708 to 589 pg/mg creatinine, p < 0.001), while no changes in these parameters were observed with gliclazide treatment. Gliclazide treatment did not affect plasma concentrations of vitamin A and E. Metformin increased plasma vitamin A from 1.84 to 2.23 µmol/l and vitamin E from 12.8 to 18.2 µmol/l, (no p value given and unsure if vitamin E value was lipid-standardized).
Type 2 DM patients, non-smokers, non-drinkers, free of chronic disease [50]	Gliclazide [n = 16] Metformin [n = 15] Diet treatment [n = 15] Time frame and dose unknown	Erythrocyte GPx, GST, catalase, MDA, and GSH	GPx, GST, and catalase activities were significantly higher, MDA levels were significantly lower in both gliclazide and metformin treatment groups compared with diet group (p < 0.05). No significant difference in antioxidant enzyme activities and levels of MDA between the drug treatment groups. No differences were seen in GSH between the three groups.
Lean polycystic ovary syndrome (BMI <25 kg/m^2) subjects and age- weight-matched healthy controls DM, hypertension and renal dysfunction were exclusion criteria [51]	Rrosiglitazone (4 mg/day) [n = 25] Metformin (850 mg twice/day) [n = 25] Age-weight-matched healthy controls [n = 35] 12 weeks	Serum MDA and TAS	TAS increased (from 0.95 to 1.21 mmol/l, p < 0.005) and MDA decreased (from 7.46 to 4.02 nmol/ml, p < 0.001) after rosiglitazone, but no changes were seen in these parameters after metformin. After treatment, MDA concentrations significantly higher in the metformin group compared with the rosiglitazone group (p < 0.05).
Healthy subjects aged 31–65 years with BMI > 27 kg/m^2 Randomized, double-blind study [52]	Rosiglitazone (4 mg/day) [n = 20] Placebo [n = 20] 6 months	Plasma peroxides	Compared with placebo, plasma peroxides decreased significantly after 6 months of rosiglitazone treatment (−15%).
Type 2 DM patients on a stable dose of oral hypoglycemic drugs for at least 6 months prior to the study, with HbA1c 7–10% and with postprandial plasma glucose > 8 mmol/l [53]	Repaglinide and diet treatment [n = 21] Repaglinide and metformin [n = 25] Diet treatment [n = 13] Metformin alone, for 2 months [n = 16]	TAS, SOD, HbA1c	TAS increased from 20.62 ± 0.9 to 24.31 ± 1.4 μgH2O2/ml/min (p < 0.05) in repaglinide-treated group; and also serum SOD activity increased from 208.1 ± 10.7 to 237.9 ± 10.6 U/l (p < 0.0004). Both showed a significant difference compared to control group. HbA1c level was decreased in repaglinide-treated group from 8.6 ± 0.97 to 8.0 ± 1.0%, compared to control group (8.3 ± 1.4–8.2 ± 1.2%, p = 0.01).
Newly diagnosed Type 2 DM patients [54]	Pioglitazone (30 mg/day) [n = 30] Metformin (1000 mg/day) [n = 50] No medication (lifestyle modification) for 3 months [n = 49]	AOPP, AGE, FRAP, enzymatic activities of PON, LCAT, LPL	Significant decreases in AOPP (from 154.20 ± 3.75 to 125.45 ± 4.08 μmol/l, p < 0.001) and AGE (from 68.62 ± 0.52 to 59.58 ± 0.91%, p < 0.001) observed in patients taking pioglitazone, whereas FRAP (from 1051.30 ± 25.54 to 1183.27 ± 46.67 μmol/l, p = 0.003) and activities of both PON (from 37.07 ± 2.19 to 48.25 ± 3.00 U/l, p < 0.001) and LPL (from 2.27 ± 0.17 to 5.03 ± 0.19 U/ml, p < 0.001) increased significantly. No changes were seen in control group, except a decrease in FRAP
15 Type 2 DM patients and 20 healthy, age-, and sex-matched controls [55]	Metformin (1700mg/day) [n = 15] Placebo [n = 20] 3 months	MDA, SOD, ascorbic acid, α-tocopherol, AOPP, AGE, NAG.	Increases in serum NAG activity (p < 0.05) and plasma MDA were found 1 month after metformin treatment, whereas plasma MDA (p < 0.001), ascorbic acid (p < 0.01), and the α-tocopherol/ (cholesterol + triglyceride) ratio (p < 0.001) increased significantly after metformin treatment.
Type 2 DM patients [56]	Metformin (850–2000mg/day) [n = 110] Placebo [n = 98] 24 weeks	HbA1c, intracellular ROS generation, AOPP, AGE.	Compared to baseline, HbA1c, AOPP, and AGE decreased significantly from 8.7 ± 1.4 to 6.9 ± 0.75% (p < 0.05), from 179.64 ± 13.6 to 120.65 ± 10.5 μmol/l (p < 0.001), and from 107 ± 10.4 to 78 ± 7.6 pmol/l (p < 0.05), respectively. Reduction in ROS generation was seen in white blood cells in patients in metformin group.
87 Type 2 DM patients and 45 healthy controls [57]	Dietary treatment only (newly diagnosed DM patients) [n = 42] Glucose-lowering treatment with average dose of metformin at 1000–1500 mg/day (diagnosed for more than 5 years) [n = 45] Healthy controls [n = 45] 3 months	Serum LDL-C oxidation, HbA1c	HbA1c level and oxidized-LDL-C/LDL-C ratio decreased from 8.37 ± 0.36 to 7.36 ± 0.59 μmol/l (p < 0.001) and from 0.082 to 0.06 (p < 0.001), respectively, after metformin.
Newly diagnosed Type 2 DM patients [58]	Metformin (1000 mg/day) [n = 50] No medication (lifestyle medication) [n = 49] 3 months	AOPP, AGE, FRAP, PON, LCAT, LPL.	Compared to baseline, a significant reduction in AOPP (from 137.52 ± 25.59 to 118.45 ± 38.42 μmol/l, p < 0.001), and AGE (from 69.28 ± 4.58, 64.31 ± 8.64%, p = 0.002) seen after metformin treatment. FRAP (from 1060.67 ± 226.69 to 1347.80 ± 251.40 μmol/l, p < 0.001) and PON (from 29.85 ± 23.18 to 37.86 ± 27.60 U/l, p = 0.012) increased significantly. Significant differences between metformin and lifestyle modification were observed only in AOPP (p = 0.007), FRAP, and AGE (p < 0.001).
Subject characteristics/test material	Study description	Outcome/biomarkers investigated	Results/comments
Simvastatin
Hypercholesterolemic subjects (with serum cholesterol > 200 mg/dl and proven vascular disease: coronary, carotid, peripheral arterial disease) [59]	Cross-over trial with two groups Group 1: simvastatin 10–40 mg/day, titrated to achieve ≥20% reduction in cholesterol after 60 days Group 2: same simvastatin treatment + vitamin E 600 mg/day with meals [n = 43] 2 months	Plasma vitamin E, 8-hour urinary 8-iso-PGF2α and oxLDL	Urinary 8-iso-PGF2α and ox-LDL was significantly decreased by simvastatin alone (both p < 0.05), but the addition of vitamin E produced no further reduction in urinary 8-iso-PGF2α or ox-LDL. Inverse correlation between 8-iso-PGF2α and vitamin E was seen (r^2 = 0.024, p = 0.318).
Simvastatin
Male subjects with previously untreated hypercholesterolemia with fasting serum cholesterol between 6.0–8.0 mmol/l and fasting Tg < 3.0 mmol/l [60]	Subjects randomly allocated to habitual diet [n = 60] or dietary treatment group [n = 60]. Each group further randomized to receive simvastatin (20 mg/day) or placebo 12 weeks	Serum α-tocopherol, β-carotene, and ascorbic acid. Serum LDL-C fraction used for the determination of diene conjugation and total peroxyl radical trapping antioxidant potential. Antioxidant potential of isolated LDL-C samples was determined.	Simvastatin treatment did not affect serum ascorbic acid, but decreased serum α-tocopherol by 16.2% and β-carotene by 19.5% and total peroxyl radical trapping potential of serum LDL-C by 16.9%. Relative antioxidant power of LDL-C preparations (LDL-C TRAP/mmol of LDL-C) increased by 17.4 Note: The crude value of α-tocopherol was not corrected for the cholesterol levels.
Hypercholesterolemic patients [61]	Three-phase protocol (1) Washout, without statin treatment (basal) for 1 month (2) Simvastatin (20 mg/day) for 2 months (3) Simvastatin (20 mg/day) + α-tocopherol (400UI/day) for 2 months [n = 25]	Plasma α-tocopherol, lycopene, retinol, β-carotene, nitrotyrosine, and GSH	The concentration of retinol increased by 37% in group 2. No difference seen for other lipid-soluble antioxidants in groups 2 and 3. Simvastatin alone and simvastatin taken with α-tocopherol decreased plasma nitrotyrosine to the same degree (p < 0.05 compared to control group). GSH concentrations were not affected by any treatment.
Simvastatin
Patients with LDL > 130 mg/dl [62]	Simvastatin (20 or 40 mg/day) [n = 72] 8 weeks	Oxidative DNA damage in lymphocytes	Simvastatin treatment decreased DNA damage, reduction of 10.5–8.8% in tail DNA, 55.5–44.5 µm in tail length, and 7.5–5.2 in tail moment (tail DNA: r = 0.586; tail length: r = 0.580; tail moment: r = 0.576 respectively, p < 0.001 for all when compared to baseline.
Subjects with LDL-C ≥ 130 mg/dl Subjects free of hepato- and renal disorders, DM, history of CVD and had not taken any cholesterol-lowering agent during the preceding 6 months [63]	Simvastatin (20–40 mg/day) administered Randomly assigned to 20 mg/day [n = 39] or 40 mg/day [n = 37] 8 weeks	Ox-LDL, TRAP, and plasma antioxidant vitamins (retinol, α-tocopherol, γ-tocopherol, coenzyme Q10 and carotenoids)	In all subjects, simvastatin treatment improved plasma antioxidant status as assessed by TRAP (increased from 1.20 to 1.23 µM, p < 0.05). Ox-LDL was significantly decreased from 63.4 to 41.5 U/l (p < 0.0001). Significant increases in the levels of retinol (p < 0.001), α-tocopherol (p < 0.001) and γ-tocopherol (p < 0.005) seen. Coenzyme Q10 and carotenoids remained unchanged.
Simvastatin
Type 2 DM patients with dyslipidemia, Type 2 DM patients without dyslipidemia and healthy control subjects [64]	Observational study Dyslipidemic Type 2 DM patients on 20 mg simvastatin daily for an average of 2 years, [n = 9] Dyslipidemic Type 2 DM patients not on simvastatin, [n = 14] Non-dyslipidemic Type 2 DM patients controls [n = 11] Healthy controls [n = 18]	Oxidative DNA damage in leukocytes; plasma MDA; TAR; HbA1c; PON activity; CRP	TAR and PON activity was significantly increased in patients under simvastatin treatment when compared to those without simvastatin treatment, whereas MDA, CRP, and DNA damages were found decreased significantly compared to patients without simvastatin treatment and patients without dyslipidemia
Atorvastatin
Normocholesterolemic Type 2 DM patients All subjects were (treated with oral glucose-lowering agents and/or insulin) [65]	Atorvastatin (10 mg/day) [n = 10] Placebo [n = 9] 3 months	LDL oxidizability (dienes production), plasma α-tocopherol	Dienes production lower in the atorvastatin group (487 vs. 538 nmol, p = 0.012) compared to placebo. Plasma α-tocopherol was decreased in the atorvastatin group (8.67 vs. 10.55 µg/ml plasma, p = 0.036) compared to the placebo group.
Atorvastatin
Subjects without clinical evidence of carotid artery disease, active liver disease and renal insufficiency and with LDL-C ≥ 130 mg/dl [66]	Atorvastatin (10 mg/day) [n = 35] 12 weeks	Plasma levels of protein-bound chlorotyrosine, nitrotyrosine, dityrosine, and orthotyrosine, plasma CRP.	Decrease in chlorotyrosine, dityrosine, and nitrotyrosine of 30, 32, and 25%, respectively, p < 0.02 each) after atorvastatin. Non-significant decreases in CRP and orthotyrosine seen (11 and 9%, respectively, p > 0.01 each).
Hyperlipidemic Type 2 DM patients with LDL-C >130 mg/dl [67]	Atorvastatin (10 mg/day), [n = 110] 24 weeks	Percentage change in free radical scavenger enzymes, SOD, GSH, GST, GPx, plasma MDA.	Compared to baseline, SOD, and GSH activities increased significantly (p < 0.001), whereas plasma MDA level significantly decreased (p < 0.001). No changes were seen in other biomarkers.
Type 2 DM patients without macroangiopathy [68]	Atorvastatin (10 mg/day), [n = 15] Vitamin C (2 g/day), [n = 13] No treatment control, [n = 14] 4 weeks	Serum IL-6, TNF-α, sVCAM-1, CRP, and ADMA.	Serum IL-6 (from 2.27 ± 0.55 to 1.36 ± 0.19 pg/ml), TNF-α (from 2.51 ± 0.54 to 1.62 ± 0.18 pg/ml), sVCAM-1 (from 484.7 ± 31.2 to 363.5 ± 13.2 ng/ml), CRP (from 3.84 ± 1.16 to 2.34 ± 0.71 mg/l) and ADMA (from 1.21 ± 0.18 to 0.72 ± 0.08 µmol/l) showed significant decreases after atorvastatin treatment (p < 0.05 compared to baseline), while no changes were seen in the other two groups.
Hypercholesterolemic patients (not taking statins or antioxidants) free of cardiovascular disease, liver disease, and renal insufficiency. Healthy controls [69]	Subjects were randomized to A) diet only [n = 15] B) diet + atorvastatin (10 mg/day) [n = 15] C) healthy control subjects [n = 20] Followed-up for 30 days after treatment	Urinary 8-iso-PGF2α and plasma vitamin E and concentrations	A reduction of 8-iso-PGF2α (−37.1%, p < 0.01) and ox-LDL (−58.9%, p < 0.01), increase of vitamin E (42%, p < 0.01) and a reduction of cholesterol (−24.9%, p < 0.01) seen after 30 days. In vitro study showed that atorvastatin dose-dependently inhibited LDL-C oxidation and 8-iso-PGF2α formation.
Type 2 DM patients [70]	Atorvastatin (10 mg/day) [n = 23] Curcumin (120 mg twice/day) [n = 23] Placebo [n = 21] 8 weeks	Plasma MDA	Plasma MDA was found decreased significantly from 3.46 ± 0.51 to 2.16 ± 0.17 nmol/ml, compared to baseline (p < 0.01) in those taking atorvastatin.
Fenofibrate
Type 2 DM patients with no complications or dyslipidemia [71]	Fenofibrate (200 mg/day) only, [n = 18] Coenzyme Q10 (200 mg/day) only, [n = 19] Fenofibrate (200 mg/day) and coenzyme Q10 (200 mg/day), [n = 19] Placebo, [n = 18] 12 weeks	HbA1c and plasma F2 isoprostanes	Fenofibrate did not result in significant changes in any markers.
Fenofibrate
Patients with combined dyslipidemia, with cholesterol in the range of 5.0–7.8 mmol/l, Tg ≥ 1.7 mmol/l 40% of the subjects had history of Type 2 DM, 65% of hypertension, 25% of CHD, 15% of previous stroke [72]	Fenofibrate (300 mg/day) [n = 20] 8 weeks to 3 months	Plasma MDA, TAS, GPx, conjugated diene formation	Fenofibrate treatment resulted in significant reduction conjugated diene from 33.7 to 19.7 µmol/l (-42%) (p < 0.0001). A tendency toward lower TAS (from 1.72 to 1.62 mmol/l, p = 0.061) and a similarly non-significant trend to decreased MDA production (from 1.95 to 1.81 µmol/l, p = 0.199) were noted. Significant increase in GPx activity (80%, from 5.8 at the baseline to 10.45 U/ml) was seen.
Lovastatin
Type 2 DM patients with dyslipidemia [73]	Policosanol (10 mg/day); [n = 16] Lovastatin (20 mg/day); [n = 16] 8 weeks treatment after 4 weeks on a cholesterol-lowering diet	Plasma TBARS	Lovastatin decreased plasma TBARS by 11.5% compared to baseline (p < 0.001).
Lovastatin
Hemodialysis patients [74]	Lovastatin (20 mg/day), [n = 30] Hypolipemic diet [n = 28] Control group [n = 13] 6 months treatment	Serum TAS and 8-OHdG	A significant decrease in 8-OHdG from 15.6 to 12.5 ng/ml (p = 0.04), and a significant increase in the TAS level from 1.28 to 1.37 mmol/l (p = 0.011) was seen in lovastatin-treated group. TAS decreased in the hypolipemic diet- treated group from 1.55 to 1.45 mmol/l (p = 0.007).
Fluvastatin
Type 2 DM patients with hyperlipidemia [75]	Fluvastatin (20 mg/day), [n = 6] Controls, [n = 6] 12 weeks.	Plasma LDL size, LHPO, TBARS, oxysterols	LHPO (from 43.3 ± 13.1 to 14.4 ± 5.1 nmol/mgLDL), TBARS (from 8.83 ± 1.11 to 4.27 ± 0.65 nmol/ml), Total oxysterols (from 61.25 ± 8.32 to 38.95 ± 6.57 ng/ml) decreased significantly after 12 weeks in treatment group compared to baseline (p < 0.05).
Gemfibrozil
Type 2 DM patients with hypertriglyceridemia [76]	Gemfibrozil (1200 mg/day) [n = 56] 3 months	Serum PON activity	Serum PON activity increased from 100.2 to 118.7 U/I, p < 0.001.
Combination
Type 2 DM patients with hypercholesterolemia (LDL cholesterol level > 100 mg/dl) [77]	Cross-over study [n = 45] Simvastatin alone (20 mg/day) Ramipril (5–10 mg/day) and simvastatin Ramipril alone Each treatment for 2 months with a washout period of 2 months.	Plasma MDA	Plasma MDA levels were decreased by 4 ± 7% (P = 0.026) and by 25 ± 4% (p < 0.001) in simvastatin alone or simvastatin with ramipril, respectively, when compared to baseline.
Type 2 DM patients with dyslipidemia [78]	Cross-over trial Simvastatin (20 mg/day), [n = 10]; Fenofibrate (200 mg/day), [n = 10] Treatment for 3 months; 2 month wash-out period, patients crossed over on other treatment for 3 months Healthy controls [n = 24]	HbA1c, uric acid, homocysteine, plasma MDA, SOD, GSH, serum ascorbic acid, serum α-tocopherol, NAG activity	Uric acid decreased from 370 ± 90 to 313 ± 107 μmol/l (p < 0.01), MDA decreased from 2.78 ± 0.40 to 2.36 ± 0.36 μmol/l, and homocysteine increased from 11.9 ± 2.8 to 16.0 ± 4.5 μmol/l (p < 0.001), in patients treated with fenofibrate, this was not found in those taking simvastatin. GSH, ascorbic acid, and NAG increased from 14.4 ± 5.0 to 11.4 ± 5.4 μmol/l (p < 0.01), 56.4 ± 23.2 to 75.0 ± 20.6 μmol/l (p < 0.001), 23.4 ± 5.7 to 31.4 ± 7.3 U/I (p < 0.001), respectively, in patients treated with simvastatin but not with fenofibrate. α-tocopherol decreased in both treatments from 18.3 ± 5.5 to 14.9 ± 3.9 mg/l (p < 0.001) in simvastatin and from 18.8 ± 5.2 to 14.7 ± 3.6 mg/l in fenofibrate.
Combination
Type 2 DM patients [79]	Rosiglitazone (4 mg/day) in addition to patients’ current therapy for 12 weeks, followed by the addition of fenofibrate (200 mg /day) for another 12 weeks, [n = 40] 24 weeks	HbA1c, Uric acid	Uric acid decreased significantly from 4.78 ± 1.1 to 4.41 ± 1.1 mg/dl (p = 0.001), whereas HbA1c decreased from 9.95 ± 9.7 to 8.85 ± 8.5% compared to baseline. Addition of fenofibrate resulted in a significantly lower uric acid concentration when compared to rosiglitazone alone (4.41 ± 1.1 mg/dl vs. 3.86 ± 0.99 mg/dl, p = 0.001)
Patients requiring statin treatment but not taking any antioxidants or statins 2 months prior to the study [80]	Simvastatin (20 mg/day) [n = 17] Pravastatin (40 mg/day) [n = 18] 6 weeks	Plasma α- and γ-tocopherol	Plasma α- tocopherol levels were equally decreased by pravastatin and simvastatin (-17.5 µg/ml, p = 0.0002 and -12.2 µg/ml, respectively, p = 0.006) when compared to baseline. Pravastatin did not significantly affect plasma γ- tocopherol levels, simvastatin produced a significant increase (22 µg/ml, p = 0.009)
Subjects with metabolic syndrome, healthy control subjects [81]	Simvastatin [n = 16] Atorvastatin [n = 14] Metabolic syndrome patients not on statin [n = 82] Healthy control subjects [n = 80] Dosage not specified. >6-month statin treatment	Retrospective analysis of oxidative stress assessed by serum levels of 8-OHdG and vitamin E.	Statin-treated subjects had higher levels of vitamin E (5.24 vs.4.61 µmol/mmol cholesterol, p = 0.02) and decreased levels of 8-OHdH (2.16 vs3.68 ng/ml, p < 0.01) compared with subjects not on statin. Statin treated subjects had similar vitamin E and 8-OHdG levels as control subjects.
Combination
Type 2 DM subjects with marked hypertriglyceridemia. All diabetic patients were treated with either metformin or a combination of metformin and a sulfonylurea to achieve HbA1c of < 9% before the study. 6-week washout/run-in period for lipid-lowering medications before subjects were randomly assigned to a treatment group [82]	(1) Atorvastatin 20 mg/day, [n = 19]; (2) Micronized fenofibrate 200 mg/day, [n = 19] 6 weeks treatment period	Plasma oxLDL, 8-iso-PGF2α , ApoB and ApoA-I, E-selectin	Atorvastatin treatment significantly reduced plasma ApoB (−43.2%, p < 0.0001), as did treatment with fenofibrate (-9.9%, p = 0.01). OxLDL was significantly reduced in atorvastatin group (−38.4%, p < 0.0001). A tendency toward decreased 8-iso-PGF2α levels in atorvastatin group (−62.1%, p = 0.06) and decreased levels of oxLDL in fenofibrate group (-8.8%, p = 0.09) were observed. Under fenofibrate treatment, the % change in plasma levels of oxLDL was significantly and directly correlated with LDL-C (r = 0.60, p = 0.006) and with the % change in soluble E-selectin levels (r = 0.64, p = 0.003). Such associations were not significant in atorvastatin group.
Combination
Type 2 DM patients with serum LDL levels > 100 mg/dl [83]	Atorvastatin, 20 mg/day, [n = 31]; Rosuvastatin, 10 mg/day, [n = 31] 3 months	TAC, TOS, LOOH	TAC increased significantly (from 0.87 ± 0.17 to 0.97 ± 0.13 mmol Trolox equiv/l, p = 0.007) in atorvastatin group. No changes seen in other markers or in patients taking rosuvastatin.
Valsartan
Hypertensive patients (BP > 140/90 mmHg) with mild diabetes or impaired glucose tolerance (HbA1c < 9%, requiring treatment by diet alone or an oral hypoglycemic) [84]	Valsartan (40–80 mg/day) – initial dose 40 mg/day, increased to 80 mg/day if the BP was still 140/90 mmHg after 1 month [n = 26] 3 months	8-OHdG and 8-isoprostanes	Urinary 8-OHdG decreased significantly from 12.12 to 8.07 ng/mg. creatinine (p = 0.001). The decrease in 8-OHdG following valsartan treatment is independent of the amelioration in %HbA1c (or glucose metabolism). In contrast, concentrations of 8-isoprostanes did not alter significantly after 3 months of treatment (283.5 vs. 302.0 pg/mg. creatinine post-treatment, p = 0.559).
Losartan
Type 2 DM patients with nephropathy [36]	Losartan (100 mg/day) [n = 678]; Matching placebo [n = 664] Mean follow-up duration of 3.4 years	Serum uric acid, HbA1c	Losartan reduced serum uric acid compared to placebo (p < 0.001). HbA1c level was not affected by losartan treatment.
Niacin
Type 2 DM patients with reduced HDL cholesterol levels and metabolic syndrome [85]	Extended-release niacin from 500 mg/day for 3 months, with escalation to 1000 mg/day every month; [n = 15] Healthy controls [n = 10]	Endothelial superoxide production, NADPH oxidase activity, and lipid oxidation of HDL as measured by electrophoresis mobility and MDA concentration.	Decreased endothelial superoxide production (p = 0.004), NADPH oxidase activity (p = 0.04), myeloperoxidase activity (p = 0.02) and myeloperoxidase content (p = 0.01) were observed in subjects taking niacin, compared to placebo. Reduced lipid peroxidation of HDL seen in subjects taking niacin only when evaluated using electrophoresis mobility (p = 0.02) but not by measuring MDA concentration (p = 0.41), compared to placebo group.
Others
Type 2 DM patients with hypertension, BP > 160/95 mmHg [37]	Captopril, [n = 16] Enalapril, [n = 16] Doses given according to patient requirement 12 weeks.	Plasma TBARS	Both captopril and enalapril treatments gave rise to significant decreases in TBARS levels from 2.35 to 1.46 nmol MDA (p < 0.05) and from 2.44 to 1.72 nmol MDA (p < 0.01), respectively.
Non-obese, normotensive patients with Type 2 DM [86]	Cross-over study Enalapril, 10 mg/day or 30 mg/day continuous-release Nifedipine, for 4 weeks, followed by 2-week washout period then crossed over to the other treatment for 4 weeks [n = 24]	LDL oxidizability, HbA1c level	Enalapril reduced LDL oxidation significantly (p = 0.001), whereas nifedipine increased LDL oxidation (p < 0.05). HbA1c level was not affected by either treatment.
Others
Hypertensive patients Healthy control subjects [87]	(1) α-blocker: doxazosin (4 mg/day), [n = 20]; (2) β-blocker: metoprolol (100 mg/day,) [n = 22]; (3) ACE inhibitor: ramipril (5 mg/day), [n = 20]; (4) angiotensin II antagonist: valsartan (80 mg/day), [n = 20]; (5) calcium channel blocker: amlodipine (10 mg/day), [n = 20]; Healthy controls [n = 51] 3 months	Erythrocyte MDA and SOD	Erythrocyte MDA decreased (p < 0.001) and SOD increased (p < 0.05) in groups 3 and 4 when compared to baseline. No obvious effect on oxidative stress was noted in other groups.
Type 2 DM patients with hypertension [88]	Carvedilol (initiated at 6.25 mg twice daily up to a maximum of 25 mg twice/day), [n = 16]; Metoprolol (initiated at 50 mg twice/day up to a maximum of 200 mg twice/day), [n = 18] In addition to patients’ current anti-hypertensive medications 5 months.	Oxidized LDL, HbA1c, and CRP, 8-isoprostane	No significant differences were observed between either groups and compared to baseline.
Others
Type 2 DM patients (aged 43–78 years) with nephropathy whose systolic arterial 200 > BP > 130 mmHg and who were absent of marked hyperglycemia (HbA1c < 8%) Patients with a history of vascular events or revascularization, severe diabetic retinopathy, current smokers were excluded. None of the patients have received ARB, diuretics, xanthine oxidase inhibitors, anti-inflammatory drugs,	Subjects were randomly assigned to (1) Candesartan 8 mg/day, [n = 11] or valsartan 80 mg/day, [n = 22] (2) Trichlormethiazide 2 mg/day [n = 33] 8 weeks	Urinary levels of 8-epi-PGF2α and 8-OHdG, normalized with creatinine.	Treatment with either candesartan or valsartan for 8 weeks reduced the levels of urinary 8-epi-PGF2α and 8-OHdG, whereas levels were not altered with trichlormethiazide treatment. Significant correlation was observed between the reduction of the urinary 8-epi-PGF2α and 8-OHdG and those of the nephropathy (urinary albumin and type IV collagen). There was no significant difference in the studied biomarkers between the candesartan and the valsartan group.
Others
or drugs with antioxidant property within 1 month before the study. Majority of the patients had been treated with ACE inhibitor or calcium channel blockers for ≥1 year [89]

Table 5. Human studies showing increased ox stress and/or depleted antioxidant status in Type 2 DM.

Subject characteristics	Biomarkers measured
Type 2 DM subjects and healthy age- and sex- matched controls. Males: Type 2 DM [n = 44], control [n = 33]; Females: Type 2 DM [n = 26], control [n = 26] All subjects had normal hepatic and endocrine functions, with HbA1c <6–7%. All patients were taking oral antidiabetic pills during the study period or the past 3–5 years, with no history of other medications. Diabetic duration ∼4.0 years. Exclusion criteria – macro- and microangiopathic complication, coronary heart disease or hypertension, life-threatening diseases such as cancer [110]	Males: Serum MDA significantly higher in DM compared with controls (0.29 vs. 0.11 pmoles/mg protein, p < 0.05). Reduced GSH was decreased in the diabetic group (195.6 vs. 294.8 pmoles/mg protein in control, p < 0.05) Females: Similar patterns observed in female groups. MDA concentrations were 0.23 vs. 0.07 pmoles/mg protein in controls, p < 0.05. Reduced GSH was 193.9 vs. 250.3 pmoles/mg protein in controls, p < 0.05.
Type 2 DM patients (HbA1c >7.2%) [n = 44] aged 51–65 years, healthy controls [n = 12]. 23 patients were previously treated with metformin (16 males, 7 females) and 21 treated with SU (16 males, 5 females) [111]	Plasma MDA and F2-isoprostanes significantly lower in the metformin treated group compared with SU-treated group, (MDA, 2.82 vs. 3.12 μmol/l, p < 0.05; F2-isoprostanes, 25.2 vs. 31.3 pg/ml, p < 0.05). These parameters were significantly lower in the control group compared with diabetic patients (MDA: 2.51μmol/l; F2-isoprostanes: 17.2 pg/ml in the control group). Plasma TAS was lowered in SU-treated group (1.02μmol/l) compared with metformin group (1.31μmol/l) and control (1.45μmol/l), but was higher in control overall compared with diabetic subjects, p < 0.05. SU-treated subjects had the lowest blood total GSH (590μmol/l) which was significantly lower than the metformin group (870μmol/l) and the control (980μmol/l), p < 0.05.
Type 2 DM patients’ mean age 52.35 years, mean duration of DM of 6.95 years [n = 64], healthy subjects’ mean age 51.02 years [n = 36] Exclusion criteria – renal, liver, heart diseases [112]	TBARS concentrations (4.53μmol/l) and SOD activity (4.85U/ml) were elevated in the diabetic group compared with the control group (TBARS: 1.36μmol/l, p < 0.001; SOD activity: 0.71, p < 0.00001). Plasma catalase activity was significantly decreased in the diabetic group (120k/l) compared with control (152k/l, p < 0.00001).
Type 2 DM patients mean age 57.2 years [n = 41]. HbA1c ∼9.1% and control subjects with normal glucose tolerance and no family history of DM, [n = 33] [113]	The serum 8-OHdG concentrations in DM subjects were significantly higher than in control subjects (5.03 vs. 0.96 pmol/ml, p < 0.01). When patients were subdivided into three groups by the presence and severity of retinopathy, subjects with proliferative diabetic retinopathy (8.27pmol/ml) had significantly higher concentrations of 8-OHdG than subjects with NPDR (4.92pmol/ml), or subjects without retinopathy (3.38pmol/ml, p < 0.01 vs. no retinopathy and NPDR). Similarly, serum 8-OHG concentrations in patients with azotemia (9.31pmol/ml) were higher than those with normoalbuminuria (3.54pmol/ml), microalbuminuria (5.74pmol/ml), or overt proteinuria (3.40pmol/ml, p < 0.01 vs. all).
38 Type 2 DM patients [n = 38] and 36 healthy age-matched controls [n = 36] Subjects not taking antioxidant supplements [114]	Multiple DNA base oxidation products, but not DNA base de-amination or chlorination products were found to be elevated in white blood cell DNA from DM patients compared with age-matched controls. No significant difference seen in 5-chlorouracil and concentrations of the base de-amination products hypoxanthine and xanthine. 8-hydroxyguanine, 5-OH uracil, 5-OH methyluracil, thymine lycol, 5-OH methyldantoin, 5-OH hydantoin, 5-OH cytosine, 2-OH adenine, 8-OH adenine, and FAPy-adenine concentrations were elevated, whereas FAPy-guanine remained unchanged. Total DNA base oxidative damage products in DM subjects was double than that found in healthy controls, p < 0.01.
Type 2 DM [n = 24] Age-, sex-, and BMI-matched subjects (obese group) [n = 19] Unmatched control group [n = 34] Exclusion criteria – presence of Prader–Willi Syndrome, hypothyroidism, known alcohol or drug abuse, congenital CVD, history of malignancy, use of glucocorticoids, and chronic renal failure or known primary renal disease. None of the participants were taking lipid-lowering drugs [115]	Plasma IL-6 concentrations were 29.3% higher in the obese group compared with the control group, DM group had a plasma IL-6 concentration 44.5% higher than the control group and 21.5% higher than the obese group, p < 0.001 for all. Ultra-sensitive CRP was not different among the groups. OxLDL was elevated 1.6 fold in the DM group compared with the control (p = 0.002). Plasma TAS was not different between the three groups.
Type 2 DM subjects (mean duration of diabetes: 8.5 years HbA1c ∼7.1%) [n = 26] 52 age-matched healthy control subjects [n = 52] All Type 2 DM patients were free of microangiopathy. Exclusion criteria – smoking, inflammatory diseases, known myocardial infarction, stroke. *8 DM subjects were on with diet and exercise, 18 subjects were on oral hypoglycemic agents [116]	Urinary 8-OHdG (11.1 ng/mg. creatinine) and isoprostane (0.87 ng/g. creatinine) were also significantly higher among diabetic subjects (p = 0.019, p = 0.009 respectively). Urinary 8OHdG level in control was 8.8 ng/mg. creatinine; urinary isoprostane 0.32 ng.g creatinine.
Type 2 DM patients (33 without diabetic complications and 27 with diabetic retinopathy, of which 21 were classified as non-proliferative diabetic retinopathy, 6 were proliferative diabetic retinopathy) [n = 60 in total] Healthy, age-matched control subjects [n = 32] Exclusion criteria – acute and chronic infections, fever, malignancy, acute, and chronic nephritis, cirrhosis, and congestive heart failure. All patients were treated with insulin only [117]	Significant higher serum MDA found in DM subjects (6.72 vs 3.12 nmol/ml for controls, p < 0.01). Serum CD in DM subjects significantly elevated (0.486 vs. 0.321, p < 0.05). DM subjects with retinopathy had higher concentration in MDA and CD compared with DM subjects without complications (7.90 vs. 5.76, p < 0.05 for MDA; 0.566 vs. 0.420, p < 0.01 for CD). A significantly higher level of 8-OHdG in DM with or without retinopathy (24.96 ng/ml) compared with normal subjects (5.89 ng/ml) was seen. DM subjects with retinopathy had a significantly higher 8-OHdG conc. compared with DM subjects with no vascular complication (26.86 vs. 23.40 ng/ml, p < 0.05). Compared with controls, serum AOPP in DM subjects was significantly higher (25.66 vs. 16.66 μmol/l, p < 0.01), as was serum protein carbonyl (4.08 vs. 3.12 nmol/ml, p < 0.01). DM subjects with retinopathy also had significantly higher AOPP and protein carbonyl compared with DM subjects without vascular complications (27.8 vs. 23.91μmol/l, p < 0.05 for AOPP; 4.60 vs. 3.65 nmol/ml, p < 0.05 for protein carbonyl).
Type 2 DM subjects (normotensive, treated with only insulin, without diabetic complications, HbA1c ∼7.67%) [n = 60] Age-matched healthy controls [n = 60]. Exclusion criteria – smoking, oral hypoglycemic agents or other antioxidant therapy [118]	MDA concentrations were significantly increased (∼2-fold) in DM patients compared with normal controls (117.8 vs. 58.9 nM/dl, p < 0.001).
Type 2 DM patients (HbA1c ∼12.5%) [n = 55] Healthy control subjects [n = 40] All patients were treated with oral hypoglycemic agents, and were not taking any other medications or vitamin supplements [119]	TBARS concentrations in DM subjects were significantly higher than in healthy controls (231 vs. 58 μmol/l, p < 0.05). Carbonyl content in DM subjects was significantly higher than in controls (12.2 vs. 3.82 nmol/mg pt, p < 0.05). Plasma NO was significantly higher in DM subjects when compared to normal subjects (58 vs. 35 μmol/l, p < 0.05). The activities of SOD (1340 U/mg), GPx (40U/mg) and CAT (198 nmol H2O2 oxidized/min/ml) in RBC were significantly lower in T2DM patients compared to normal (1620U/mg, 52U/mg, 266 nmol H2O2 oxidized/min/ml), p < 0.05 respectively). Plasma vitamin A (1.75μmol/l), beta-carotene (2.23μmol/l), Vitamin C (41μmol/l), Vitamin E (16.2μmol/l), and uric acid (0.12 mmol) were all significantly lower in DM patients compared to controls (3.24, 3.86, 78, 21.4 μmol/l, 0.14 mmol/l, p < 0.05 for all).

Table 6. Antioxidant supplementation studies in Type 2 DM subjects.

Subjects characteristics/ test material	Study description	Outcome/biomarkers investigated	Information on existing treatment
Type 2 DM subjects meeting the following criteria: DM onset after 35 years of age, at least 5-year disease without insulin use, FPG ≧7.8 mmol/l, BMI <33 kg/m^2, serum creatinine <2.0 mg/dl, Exclusion criteria included history of ketoacidosis/onset of diabetes before age 35, smoking, use of vitamin supplements, treatment with glucocorticoids, thyroid hormone, lipid-lowering agents, or other drugs known to affect serum lipids, urine protein excretion >250 mg/d and serum α-tocopherol levels >28μmol/l [138]	Subjects received placebo, 750 mg sucrose per capsule as washout, then antioxidant treatment, (24 mg β-carotene, 1000 mg ascorbic acid, and 800IU α-tocopherol/day) Subjects followed post supplementation for 8 weeks. Treatment duration, placebo for 8 weeks and antioxidant for 12 weeks. Normal control subjects, age- and sex-matched to DM subjects [n = 20]	Antioxidant treatment had no effect on glycemic control, glycohemoglobin or serum lipids, but significantly increased LDL oxidation lag phase from 55 to 129 min; conjugated dienes decreased from 1.23 to 0.62 OD units; TBARS decreased from 78 to 33 nmol MDA/mg LDL protein (p < 0.0001 compared to control group).	No information given
Type 2 DM subjects and healthy controls Exclusion criteria included smoking, use of antioxidant supplements, hypolipidemic drugs, beta-blockers, or NSAID, renal or liver dysfunction, and alcohol consumption > 1oz/day [139]	All subjects supplemented with RRR-α -tocopherol (1200IU/day), following a 2-month washout. (1) Type 2 DM subjects without macrovascular complications [n = 24] (2) Type 2 DM patients with macrovascular complications [n = 23] (3) Age-, sex-, and BMI- matched healthy control subjects [n = 25] Treatment duration, 3 months.	hsCRP decreased in all three groups after supplementation compared to both baseline and washout phases (p < 0.02). IL-6 concentrations significantly decreased following supplementation in all three groups, p < 0.02. Compared to matched controls, group 2 showed significantly elevated hsCRP, all DM patients had increased levels of monocyte IL-6.	No information given
Type 2 DM subjects with urinary albumin excretion rate between 30 and 300 mg/24 h. Exclusion criteria included SBP > 200mmHg, DBP > 110mmHg, GFR < 40  ml/min/1.73 m^2 , prior MI or congestive heart failure. Treatment with ACE-inhibitors (n = 28)/ vitamin E and C supplements (n = 3) was stopped and BP was strictly monitored and controlled at < 180 mmHg at least 8 weeks before study commenced [6]	(1) Treatment group (total dose of 1250 mg vitamin C and 680 IU of d-α-tocopherol/day) [n = 15] (2) Placebo group, 5 matching placebo tablets [n = 14]	A significant decrease in urinary albumin excretion rate from 243 in the placebo to 197 mg/24 h, (p = 0.04) in the treatment group. No significant changes were seen in blood pressure, HbA1c, FPG, serum creatinine, and cholesterol with active treatment.	No information given
Type 2 DM subjects (FPG ≥ 7.8 mmol/l, a mean of 4.5 years for diabetes) Exclusion criteria –included evidence of cerebrovascular, peripheral vascular or ischemic heart disease, diabetic retinopathy requiring treatment, BP > 160/90mmHg, TC > 7.5 mmol/l, urinary albumin:creatinine ratio elevated (> 2.5 mg/mmol creatinine for men, > 3.5 for women) or serum creatinine > 100μmol/l [132]	Subjects randomized to (1) 1600IU α-tocopherol, [n = 48] (2) Placebo, [n = 21] Treatment duration, 8 weeks.	α-tocopherol treatment increased plasma vitamin E from 28.2 to 65.9 μmol/l (p < 0.01). No significant changes in basal blood flow or on vasodilation to low or high doses of the endothelium-independent vasodilator sodium nitroprusside or the endothelium-dependent vasodilators acetylcholine and bradykinin, were seen in either group.	48 subjects were either treated with diet alone [n = 17], sulphonylureas [n = 20], metformin [n = 5], or both [n = 6].
Patients with uncomplicated Type 2 DM controlled by diet or oral hypoglycemics Exclusion criteria, SBP > 160mmHg, DBP >90 mmHg, TC > 7.0 mmol/l, proteinurea, significantly impaired renal function, clinical evidence of neuropathy or atherosclerosis [140]	Subjects randomized to (1) Vitamin C (1500 mg/day) [n = 18] (2) Placebo [n = 17] Treatment duration, 3 weeks	Plasma ascorbic acid increased from 58 at baseline to 122 μmol/l, p < 0.01 following supplementation. Plasma 8-epi-PGF2α, blood pressure, lipid profiles, and endothelial function were not significantly different from baseline/placebo following vitamin C supplementation.	Metformin, sulphonylureas, ACE inhibitors, diuretics, calcium channel blockers
Type 2 DM patients with diabetic complications, retinopathy (7), neuropathy (5), nephropathy (2) and cataract (1). All subjects were with evidence of cardiovascular complications: hypertension (8), atrial fibrillation (2), angina (5), heart failure (1), cerebrovascular disease (4) and PVD (3) and one with below knee amputation [131]	Cross-over study [n = 9] first treatment – 500 mg vitamin C and 400IU vitamin E/day Treatment duration, 4 weeks; 4-week washout period. Second treatment – 1000 mg vitamin C and 800IU vitamin E/day Treatment duration, 4 weeks.	Vitamin E level increased after moderate dose and further after higher dose, 59.8 vs 36.4µmol/l, p < 0.001 and 72.7 vs 30.8µmol/l, p < 0.001, respectively. Total antioxidant capacity increased after treatment 508.2 vs 436.4 µmol/l trolox eq., p < 0.01 (moderate); 519.3 vs 440.8 µmol/l trolox eq., p < 0.01 (high). Lipid hydroperoxides were decreased more after the 1st, than after the 2nd treatment (6.1 vs. 12.1 μmol/l, p < 0.01; 8.0 vs. 11.6 μmol/l, p < 0.05).	Individual medication details are not given, but subjects were on sulphonylureas and/or metformin or insulin, or diet alone.
Female Type 2 DM patients. Exclusion criteria included insulin treatment, hypertension, hormonal therapy, smoking and ingestion of antioxidant supplements at least 3 months before the study, ingestion of hypolipidemic, and NSAID, intake of garlic or fish oil, renal or liver dysfunction poorly accessible veins and alcohol consumption [134]	(1) 800IU α -tocopherol/day [n = 13] (2) Placebo [n = 21] Treatment duration, 6 weeks	α -tocopherol did not significantly alter concentrations urea, creatinine, uric acid, HDL, serum MDA and HbA1c. A 46% reduction in erythrocyte MDA was seen in the treatment group in comparison with only 10% in placebo, p < 0.0001. A reduction in erythrocyte CuZn-SOD activity (from 1083 to 876.4 U/g, p < 0.0001) seen in the treatment group	All subjects were treated with oral hypoglycemics or diet, but no information was available as to what treatment each subject was on
Subjects were previously diagnosed of Type 2 DM or were on oral hypoglycemic medication. Exclusion criteria included prior or current use of vitamin E/tocopherol supplements, Type 1 DM, use of insulin, previous coronary or cerebrovascular event ≦6 months, smoking, premenopausal women regular use of nitrate medication, anti-inflammatories, BMI ≧ 35 kg/m^2, elevated serum creatinine or alcohol intake (> 40 g/day men or > 30 g/day for women) [127]	Randomized in a double-blind, placebo-controlled trial to (1) 500 mg RRR-α-tocopherol/day [n = 19] (2) 500 mg mixed tocopherols (60% γ-, 25% δ- and 15% α-tocopherol)/day [n = 20] (3) Placebo [n = 19] Treatment duration, 6 weeks *3-week washout period prior to the study. Subjects ceased all vitamin, antioxidant/ fish oil supplements	Treatment with α-tocopherol and mixed tocopherols significantly increased blood pressure and heart rate versus placebo. There was no significant difference between the two treatment groups. Plasma total F2-isoprostane significantly reduced following either treatment versus placebo, but urinary F2-isoprostane not affected.	Antihypertensives, oral hypoglycemics, aspirin, lipid lowering therapy, BP treatment
Type 2 DM patients Exclusion criteria included body mass index (in kg/m^2) > 35; use of insulin, nonsteroidal anti-inflammatory drugs, or nitrate medication; smoking; use of vitamin E supplements; any recent (in previous 6mo) coronary or cerebrovascular event; impaired renal function (serum creatinine > 110μmol/l for men and > 100μmol/l for women); and alcohol intake > 40 g/d for men and > 30 g/d for women. All volunteers ceased consuming any vitamin, antioxidant, or fish oil supplements for ≥ 3wk before study entry [133]	Subjects randomized to (1) 500 mg RRR-α-tocopherol/day [n = 18] (2) 500 mg mixed tocopherols (75 mg α-, 315 mg γ- and 110 mg δ- tocopherol) [n = 19] (3) Placebo [n = 18] Treatment duration, 6 weeks *3-week washout period prior to the study. Subjects ceased all vitamin, antioxidant/ fish oil supplements	Plasma total F2-isoprostane significantly (P = 0.001) reduced following either treatment versus placebo, but urinary F2-isoprostane not affected. No significant changes seen in erythrocyte SOD and GPx after any supplementation regimen.	Percentage of participants on oral hypoglycemics, (58%), antihypertensives, (51%), lipid-lowering drugs, (53%), aspirin, (38%).
Ambulatory outpatients > 65 years of age with no acute cardiovascular, neurologic event in the prior 6 months, no history of active tobacco smoking and no oral intake of vitamin supplements in the last 4 weeks. Medical treatment of these subjects was stable for the last 3 months with an HbA1c ≦ 9% [n = 36] [129]	Subjects randomized to (1) Placebo [n = 12] (2) Vitamin C (0.5 g/day) [n = 12] (3) Vitamin C (1 g/day) [n = 12] Treatment duration, 12 weeks	Significant increase in cellular GSH was observed (0.60 vs. 0.33 nmol/mg protein in the placebo group, p < 0.01) in patients on 0.5 g vitamin C/day. Significant increases in cellular GSH (0.93 vs. 0.33 nmol/mg proteins in the placebo, p < 0.01), seen in those on 1.0 g vitamin C/day. Vitamin C had no effect on the vitamin E content of HDL in any group. At week 12, no significant difference was seen in lipid peroxidation/oxidative stress markers (conjugated dienes, TBARS) and susceptibility of LDL and HDL to oxidation in the two treatment groups compared to placebo.	Individual medication details are not given, but subjects on glibenclamide, metformin or insulin
Type 2 DM patients with diabetes for >= 1 year and no clinical evidence of overt vascular diseases, acute or chronic inflammatory diseases [141]	Subjects randomized to (1) Vitamin C (1 g/day) [n = 14] (2) Acetate cellulose placebo 1000 mg/day, [n = 13] Treatment period, 6 weeks	MDA significantly decreased at fasting (p = 0.006) and postprandial states (p < 0.001) in vitamin C group, compared to placebo group. No significant differences were seen in fasting and postprandial lipid profile.	Subjects were on standard oral hypoglycemic agents, none on lipid-lowering drugs, hormone replacement therapy and diuretics, β-blockers, and aspirin.
Type 2 DM patients with no history of other chronic diseases, kidney stones, hyperparathyroidism, pregnancy and lactation, current insulin treatment and treatment for weight reduction [142]	(1) Vitamin E (800 mg/day) [n = 37] (2) Placebo[n = 34] Treatment duration, 2 months	Tg decreased significantly in vitamin E group (212 ± 85 mg/dl), compared to placebo group (254 ± 170 mg/dl). No significant differences were seen in serum fasting glucose, HbA1c and β-cell function after vitamin E supplementation, compared to placebo group.	No information given

Shin D, Cho YM, Lee S, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig. 2014;34(6):383–393.

 PubMed Web of Science ®Google Scholar

Dhawan S, Singh B, Garg SK, et al. Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. Clin Pharmacokinet. 2006;45(3):317–324.

 PubMed Web of Science ®Google Scholar

Huber M, Bolbrinker J, Kreutz R. Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Clin Exp Hypertens. 2006;28(7):631–633.

 PubMed Web of Science ®Google Scholar

Gross AS, Bridge S, Shenfield GM. Pharmacokinetics of tolbutamide in ethnic Chinese. Br J Clin Pharmacol. 1999;47(2):151–156.

 PubMed Web of Science ®Google Scholar

Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol. 1999;39(2):172–179.

 PubMed Web of Science ®Google Scholar

Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther. 1998;36(12):636–641.

 PubMed Web of Science ®Google Scholar

Chu KM, Hu OY, Pao LH, et al. Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. J Pharm Pharm Sci. 2007;10(4):411–419.

 PubMed Web of Science ®Google Scholar

Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006;61(1):70–78.

 PubMed Web of Science ®Google Scholar

Xu P XD, Zhu Y, Wang F, et al. Pharmacokinetic properties and bioequiavailability of miglitol in Chinese subjects. Chinese J Hosp Pharm. 2005;25(5):409–411.

 Google Scholar

Krishna R, Bergman A, Larson P, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol. 2007;47(2):165–174.

 PubMed Web of Science ®Google Scholar

Mignini F, Tomassoni D, Streccioni V, et al. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. Clin Exp. 2008;30(2):95–108.

 Google Scholar

Deng S, Chen XP, Cao D, et al. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin Ther. 2009;31(6):1256–1263.

 PubMed Web of Science ®Google Scholar

Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69(3):477–487.

 PubMed Web of Science ®Google Scholar

Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995;76(2):80–3A.

 PubMed Web of Science ®Google Scholar

Bergman E, Matsson EM, Hedeland M, et al. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J Clin Pharmacol. 2010;50(9):1039–1049.

 PubMed Web of Science ®Google Scholar

Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25(2):459–471.

 PubMed Web of Science ®Google Scholar

Kosoglou T, Zhu Y, Statkevich P, et al. Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. Eur J Clin Pharmacol. 2011;67(5):483–492.

 PubMed Web of Science ®Google Scholar

Heintz B, Verho M, Brockmeier D, et al. Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure. J Cardiovasc Pharmacol. 1993;22(Suppl 9):S36–S42.

 PubMedGoogle Scholar

Tamimi JJ S, Alam SM II, et al. Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. Biopharm Drug Dispos. 2005;26(8):335–339.

 PubMed Web of Science ®Google Scholar

Rohatagi S, Lee J, Shenouda M, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol. 2008;48(11):1309–1322.

 PubMed Web of Science ®Google Scholar

Riess W, Dubach UC, Burckhardt D, et al. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol. 1977;12(5):375–382.

 PubMed Web of Science ®Google Scholar

Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension. 2011;58(1):2–7.

 PubMed Web of Science ®Google Scholar

Bain SC, Le Guen CA, Lunec J, et al. Comparison of the free radical scavenging activity of captopril versus enalapril: a three month in vivo study in hypertensive diabetic patients. J Hum Hypertens. 1991;5(6):511–515.

 PubMed Web of Science ®Google Scholar

Abou-Auda HS. Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. Int J Clin Pharmacol Ther. 1998;36(5):275–281.

 PubMed Web of Science ®Google Scholar

Xu T, Bao S, Geng P, et al. Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. J Chronomatogr B Analyt Technol Biomed Life Sci. 2013;937:606.

 Web of Science ®Google Scholar

Cainazzo MM, Pinetti D, Savino G, et al. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. Drugs Exp Clin Res. 2005;31(3):115–121.

 PubMedGoogle Scholar

Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of atenolol. Basic Clin Pharmacol Toxicol. 2006;98(6):555–558.

 PubMed Web of Science ®Google Scholar

Liu XH, Li XM, Han CC, et al. Effects of combined therapy with glipizide and Aralia root bark extract on glycemic control and lipid profiles in patients with type 2 diabetes mellitus. J Sci Food Agr. 2015;95(4):739–744.

 PubMed Web of Science ®Google Scholar

Fava D, Cassone-Faldetta M, Laurenti O, et al. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes. Diabet Med. 2002;19(9):752–757.

 PubMed Web of Science ®Google Scholar

Signorini AM, Fondelli C, Renzoni E, et al. Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus. Curr Ther Res Clin E. 2002;63(7):411–420.

 Web of Science ®Google Scholar

Formoso G, De Filippis EA, Michetti N, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev. 2008;24(3):231–237.

 PubMed Web of Science ®Google Scholar

Memisogullari R, Turkeli M, Bakan E, et al. Effect of metformin or gliclazide on lipid peroxidation and antioxidant levels in patients with diabetes mellitus. Turk J Med Sci. 2008;38(6):545–548.

 Web of Science ®Google Scholar

Yilmaz M, Bukan N, Ayvaz G, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333–3340.

 PubMed Web of Science ®Google Scholar

Manning PJ, Sutherland WH, Walker RJ, et al. The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res Clin Pract. 2008;81(2):209–215.

 PubMed Web of Science ®Google Scholar

Tankova T, Koev D, Dakovska L, et al. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract. 2003;59(1):43–49.

 PubMed Web of Science ®Google Scholar

Mirmiranpour H, Mousavizadeh M, Noshad S, et al. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial. J Diab Compl. 2013;27(5):501–507.

 Google Scholar

Skrha J, Prazny M, Hilgertova J, et al. Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol. 2007;63(12):1107–1114.

 PubMed Web of Science ®Google Scholar

Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011;93(1):56–62.

 PubMed Web of Science ®Google Scholar

Nakhjavani M, Morteza A, Asgarani F, et al. Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients. Redox Rep. 2011;16(5):193–200.

 PubMed Web of Science ®Google Scholar

Esteghamati A, Eskandari D, Mirmiranpour H, et al. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr. 2013;32(2):179–185.

 PubMed Web of Science ®Google Scholar

De Caterina R, Cipollone F, Filardo FP, et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation. 2002;106(20):2543–2549.

 PubMed Web of Science ®Google Scholar

Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002;287(5):598–605.

 PubMed Web of Science ®Google Scholar

Pereira EC, Bertolami MC, Faludi AA, et al. Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients. Free Radic Biol Med. 2004;37(9):1440–1448.

 PubMed Web of Science ®Google Scholar

Shin MJ, Cho EY, Jang Y, et al. A beneficial effect of simvastatin on DNA damage in 242 T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Clin Chim Acta. 2005;360(1–2):46–51.

 PubMed Web of Science ®Google Scholar

Shin MJ, Chung N, Lee JH, et al. Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients. Int J Cardiol. 2007;118(2):173–177.

 PubMed Web of Science ®Google Scholar

Manfredini V, Biancini GB, Vanzin CS, et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem Funct. 2010;28(5):360–366.

 PubMed Web of Science ®Google Scholar

Oranje WA, Sels JP, Rondas-Colbers GJ, et al. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta. 2001;311(2):91–94.

 PubMed Web of Science ®Google Scholar

Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289(13):1675–1680.

 PubMed Web of Science ®Google Scholar

Save V, Patil N, Moulik N, et al. Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther. 2006;11(4):262–270.

 PubMed Web of Science ®Google Scholar

Tousoulis D, Antoniades C, Vasiliadou C, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmetrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart. 2007;93(2):244–246.

 PubMed Web of Science ®Google Scholar

Cangemi R, Loffredo L, Carnevale R, et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J. 2008;29(1):54–62.

 PubMed Web of Science ®Google Scholar

Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008;9(4):243–250.

 PubMed Web of Science ®Google Scholar

Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002;56(11):1137–1142.

 PubMed Web of Science ®Google Scholar

Tkac I, Molcanyiova A, Javorsky M, et al. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res. 2006;53(3):261–264.

 PubMed Web of Science ®Google Scholar

Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res. 2002;22(3–4):89–99.

 PubMedGoogle Scholar

Mastalerz-Migas A, Reksa D, Pokorski M, et al. Comparison of a statin vs. hypolipemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol. 2007;58(Suppl 5(Pt 1)):363–370.

 PubMedGoogle Scholar

Guan JZ, Murakami H, Yamato K, et al. Effects of fluvastatin in type 2 diabetic patients with hyperlipidemia: reduction in cholesterol oxidation products and VCAM-1. J Atheroscler Thromb. 2004;11(2):56–61.

 PubMedGoogle Scholar

Balogh Z, Seres I, Harangi M, et al. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab. 2001;27(5 Pt 1):604–610.

 PubMed Web of Science ®Google Scholar

Koh KK, Son JW, Ahn JY, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004;44(2):180–185.

 PubMed Web of Science ®Google Scholar

Skrha J, Stulc T, Hilgertova J, et al. Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol. 2004;493(1–3):183–189.

 PubMed Web of Science ®Google Scholar

Seber S, Ucak S, Basat O, et al. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;71(1):52–58.

 PubMed Web of Science ®Google Scholar

Werba JP, Cavalca V, Veglia F, et al. A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 2007;193(1):229–233.

 PubMed Web of Science ®Google Scholar

Cangemi R, Loffredo L, Carnevale R, et al. Statins enhance circulating vitamin E. Int J Cardiol. 2008;123(2):172–174.

 PubMed Web of Science ®Google Scholar

Hogue JC, Lamarche B, Tremblay AJ, et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metab Clin Exp. 2008;57(3):380–386.

 PubMed Web of Science ®Google Scholar

Koksal M, Eren MA, Turan MN, et al. The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur J Intern Med. 2011;22(3):249–253.

 PubMed Web of Science ®Google Scholar

Khanna HD, Sinha MK, Khanna S, et al. Oxidative stress in hypertension: association with antihypertensive treatment. Indian J Physiol Pharmacol. 2008;52(3):283–287.

 PubMedGoogle Scholar

Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010;121(1):110–122.

 PubMed Web of Science ®Google Scholar

Rachmani R, Lidar M, Brosh D, et al. Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study. Diabetes Res Clin Pract. 2000;48(2):139–145.

 PubMed Web of Science ®Google Scholar

Baykal Y, Yilmaz MI, Celik T, et al. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens. 2003;21(6):1207–1211.

 PubMed Web of Science ®Google Scholar

Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20(7):777–783.

 PubMed Web of Science ®Google Scholar

Sawada T, Takahashi T, Yamada H, et al. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens. 2009;23(3):188–195.

 PubMed Web of Science ®Google Scholar

Mahboob M, Rahman MF, Grover P. Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic patients. Singapore Med J. 2005;46(7):322–324.

 PubMedGoogle Scholar

Faure P, Wiernsperger N, Polge C, et al. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci. 2008;114(3):251–256.

 PubMed Web of Science ®Google Scholar

Turk HM, Sevinc A, Camci C, et al. Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetol. 2002;39(3):117–122.

 PubMed Web of Science ®Google Scholar

Shin CS, Moon BS, Park KS, et al. Serum 8-hydroxy-guanine levels are increased in diabetic patients. Diabetes Care. 2001;24(4):733–737.

 PubMed Web of Science ®Google Scholar

Rehman A, Nourooz-Zadeh J, Moller W, et al. Increased oxidative damage to all DNA bases in patients with type II diabetes mellitus. FEBS Lett. 1999;448(1):120–122.

 PubMed Web of Science ®Google Scholar

Stringer DM, Sellers EA, Burr LL, et al. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes. 2009;10(4):269–277.

 PubMed Web of Science ®Google Scholar

Nakanishi S, Suzuki G, Kusunoki Y, et al. Increasing of oxidative stress from mitochondria in type 2 diabetic patients. Diabetes Metab Res Rev. 2004;20(5):399–404.

 PubMed Web of Science ®Google Scholar

Pan HZ, Zhang H, Chang D, et al. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol. 2008;92(4):548–551.

 PubMed Web of Science ®Google Scholar

Kalaivanam KN, Dharmalingam M, Marcus SR. Lipid peroxidation in type 2 diabetes mellitus. Int J Diab Dev Ctries. 2006;26(1):30–32.

 Google Scholar

Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008;45(1):41–46.

 PubMed Web of Science ®Google Scholar

Anderson JW, Gowri MS, Turner J, et al. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr. 1999;18(5):451–461.

 PubMed Web of Science ®Google Scholar

Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med. 2000;29(8):790–792.

 PubMed Web of Science ®Google Scholar

Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591.

 PubMed Web of Science ®Google Scholar

Gazis A, White DJ, Page SR, et al. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet Med. 1999;16(4):304–311.

 PubMed Web of Science ®Google Scholar

Darko D, Dornhorst A, Kelly FJ, et al. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. Clin Sci. 2002;103(4):339–344.

 PubMed Web of Science ®Google Scholar

Nuttall SL MU, Kendall MJ, Dunne F. Short-term antioxidant supplementation reduces oxidative stress in elderly patients with type 2 diabetes mellitus a pilot study. Pract Diabetes. 2002;19(7):199–202.

 Google Scholar

Ble-Castillo JL, Carmona-Diaz E, Mendez JD, et al. Effect of alpha-tocopherol on the metabolic control and oxidative stress in female type 2 diabetics. Biomed Pharmacother. 2005;59(6):290–295.

 PubMed Web of Science ®Google Scholar

Ward NC, Wu JH, Clarke MW, et al. The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Hypertens. 2007;25(1):227–234.

 PubMed Web of Science ®Google Scholar

Wu JH, Ward NC, Indrawan AP, et al. Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem. 2007;53(3):511–519.

 PubMed Web of Science ®Google Scholar

Tessier DM, Khalil A, Trottier L, et al. Effects of vitamin C supplementation on antioxidants and lipid peroxidation markers in elderly subjects with type 2 diabetes. Arch Gerontol Geriatr. 2009;48(1):67–72.

 PubMed Web of Science ®Google Scholar

Mazloom Z, Hejazi N, Dabbaghmanesh MH, et al. Effect of vitamin C supplementation on postprandial oxidative stress and lipid profile in type 2 diabetic patients. Pakistan J Biol Sci: PJBS. 2011;14(19):900–904.

 PubMedGoogle Scholar

Shab-Bidar S, Mazloum Z, Mousavi-Shirazifard Z. Daily vitamin E supplementation does not improve metabolic and glycemic control in type 2 diabetic patients: a double blinded randomized controlled trial. J Diabetes. 2013;5(1):57–58.

 PubMed Web of Science ®Google Scholar